首页> 美国卫生研究院文献>Critical Care >Clinical review: Splanchnic ischaemia
【2h】

Clinical review: Splanchnic ischaemia

机译:临床评论:内脏缺血

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inadequate splanchnic perfusion is associated with increased morbidity and mortality, particularly if liver dysfunction coexists. Heart failure, increased intra-abdominal pressure, haemodialysis and the presence of obstructive sleep apnoea are among the multiple clinical conditions that are associated with impaired splanchnic perfusion in critically ill patients. Total liver blood flow is believed to be relatively protected when gut blood flow decreases, because hepatic arterial flow increases when portal venous flow decreases (the hepatic arterial buffer response [HABR]). However, there is evidence that the HABR is diminished or even abolished during endotoxaemia and when gut blood flow becomes very low. Unfortunately, no drugs are yet available that increase total hepato-splanchnic blood flow selectively and to a clinically relevant extent. The present review discusses old and new concepts of splanchnic vasoregulation from both experimental and clinical viewpoints. Recently published trials in this field are discussed.
机译:内脏血流灌注不足会增加发病率和死亡率,特别是如果肝功能不全并存时。心力衰竭,腹腔内压力增高,血液透析和阻塞性睡眠呼吸暂停的存在是重症患者内脏血流灌注受损相关的多种临床症状。人们认为,当肠道血流量减少时,总肝血流量受到相对保护,因为当门静脉血流量减少时(肝动脉缓冲反应[HABR]),肝动脉流量就会增加。但是,有证据表明,在内毒素血症期间以及当肠道血流量变得非常低时,HABR会降低甚至消失。不幸的是,尚无可选择性地并在临床上相关程度增加总肝内脏血流量的药物。本综述从实验和临床角度讨论了内脏血管调节的新旧概念。讨论了该领域最近发表的试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号